CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
肿瘤浸润性浆细胞靶点作为免疫疗法的来源
英文原题：Tumor-infiltrating plasma cell targets as a source for immunotherapies.
查看英文原题
Tumor-infiltrating plasma cell targets as a source for immunotherapies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
肿瘤浸润性浆细胞是免疫治疗的关键应答者。在本期Cancer Cell中，Meyerhoff等人表明，来自抗PD-1治疗患者肺部病灶的浆细胞靶向瓜氨酸化蛋白。用这些浆细胞的scFv工程化CAR-T 细胞显示出抗肿瘤特异性且无不良影响，从而确定了治疗机会。
展开英文摘要原文
Tumor-infiltrating plasma cells are key responders to immunotherapy. In this issue of Cancer Cell, Meyerhoff et al. show that plasma cells from lung lesions of anti-PD-1-treated patients target citrullinated proteins. Engineering CAR T cells with these plasma cells scFv reveals anti-tumor specificity without adverse effects, identifying therapeutic opportunities.
论文信息
- 作者
- Lattanzi G、Hollern D
- 第一作者单位
- Nomis Center for Immunobiology and Microbial Pathogenesis, Salk Cancer Center, Salk Institute for Biological Studies, La Jolla, CA, USA.United States
- 通讯作者单位
- Nomis Center for Immunobiology and Microbial Pathogenesis, Salk Cancer Center, Salk Institute for Biological Studies, La Jolla, CA, USA; University of California San Diego, School of Biological Sciences, San Diego, CA, USA; University of California San Diego, Department of Radiation Medicine & Applied Sciences, San Diego, CA, USA. Electronic address: dhollern@salk.edu.United States
- 文献类型
- 评论
- 期刊
- Cancer cell2026 Sep 14
- 原文标识
- PubMed 42508409 · DOI 10.1016/j.ccell.2026.06.020